Addrenex acquires promising narcolepsy therapy from SK Holdings
This article was originally published in Scrip
Executive Summary
Addrenex Pharmaceuticals has acquired global rights outside east Asian markets to SK Holdings' ADX-N05, an early development-stage molecule with potential in narcolepsy and other CNS indications.
You may also be interested in...
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Asahi Paying $1.3bn For One-Product Veloxis
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.
Ebb TIDES As Takeda’s Dengue Contender Weaker At 18 Months
Takeda's TAK-003 generally positive in new 18-month analysis, but efficacy falls versus 12 months and lowest effectiveness again seen against serotype 3.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports